The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 10, 2019

Filed:

Jun. 27, 2018
Applicant:

Yale University, New Haven, CT (US);

Inventor:

Tarek M. Fahmy, New Haven, CT (US);

Assignee:

Yale University, New Haven, CT (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/127 (2006.01); A61K 47/24 (2006.01); A61K 47/40 (2006.01); B82Y 5/00 (2011.01); A61K 38/18 (2006.01); A61K 38/20 (2006.01); A61K 31/343 (2006.01); A61K 47/58 (2017.01); A61K 47/69 (2017.01); A61K 47/68 (2017.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 9/127 (2013.01); A61K 9/0019 (2013.01); A61K 9/1271 (2013.01); A61K 9/1273 (2013.01); A61K 9/1277 (2013.01); A61K 9/5153 (2013.01); A61K 31/343 (2013.01); A61K 38/1841 (2013.01); A61K 38/2013 (2013.01); A61K 47/24 (2013.01); A61K 47/40 (2013.01); A61K 47/58 (2017.08); A61K 47/6849 (2017.08); A61K 47/6937 (2017.08); A61K 47/6951 (2017.08); B82Y 5/00 (2013.01); C07K 16/2812 (2013.01);
Abstract

Compositions for delivery of growth factors needed for stable Tregs and methods of use thereof are provided. In preferred embodiments, the compositions can induce, increase, or enhance a functionally robust induced CD4 Treg population (e.g., Foxp3+ Treg) in vivo or ex vivo. The compositions generally include delivery vehicles including TGF-β and IL-2. Delivery vehicles include, for example, polymeric particles, silica particles, liposomes, or multilamellar vesicles. The TGF-β and IL-2 are typically co-loaded into, attached to the surface of, and/or enclosed within the delivery vehicle into the same particle for simultaneous co-delivery to cells such as T cells. Preferably the delivery vehicles are targeted to CD4. The compositions and cells treated therewith can be used in various methods of treating, for example, inflammation, inflammatory and autoimmune diseases and disorders, and inducing or maintaining tolerance including graft and transplant tolerance.


Find Patent Forward Citations

Loading…